MARKET

SVRA

SVRA

Savara Inc
NASDAQ
2.630
-0.130
-4.71%
Opening 12:32 03/14 EDT
OPEN
2.845
PREV CLOSE
2.760
HIGH
2.940
LOW
2.615
VOLUME
359.95K
TURNOVER
--
52 WEEK HIGH
5.34
52 WEEK LOW
2.255
MARKET CAP
451.36M
P/E (TTM)
-5.9075
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SVRA last week (0303-0307)?
Weekly Report · 4d ago
Savara’s Innovative Testing and BLA Submission Drive Buy Rating Amid Market Growth Potential
TipRanks · 03/06 16:06
Savara Launches New Dried Blood Spot Test For APAP Diagnosis
NASDAQ · 03/06 14:34
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Barchart · 03/06 07:05
Savara Inc <SVRA.OQ> expected to post a loss of 11 cents a share - Earnings Preview
Reuters · 03/05 11:02
Savara Announces Participation in the Leerink Global Healthcare Conference
Barchart · 03/03 15:15
Weekly Report: what happened at SVRA last week (0224-0228)?
Weekly Report · 03/03 09:12
Savara Insiders Lose Out As Stock Sinks To US$2.56
Simply Wall St · 02/26 10:39
More
About SVRA
More
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Recently
Symbol
Price
%Change

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.